Abstract: Methods and systems for efficient and cost-effective production of lantibiotics. The methods and systems are capable of producing lantibiotics having high purity suitable for pharmaceutical use.
Type:
Grant
Filed:
January 11, 2018
Date of Patent:
July 17, 2018
Assignee:
ImmuCell Corporation
Inventors:
Joseph H. Crabb, John W. Zinckgraf, Hanna Froebe
Abstract: Disclosed is a method for purifying a antibiotic from a crude or partially purified solution containing the lantibiotic. In preferred embodiments, the lantibiotic is nisin, although the common structural features of lantibiotics dictate the effectiveness of the disclosed purification methods for other members of the lantibiotic genus. The method includes the step of forming an incubation mixture comprising the solution containing the lantibiotic and a proteolytic enzyme, and incubating the mixture under conditions optimized for selective proteolytic activity.
Abstract: Disclosed is a method for purifying a lantibiotic from a crude or partially purified solution containing the lantibiotic. In preferred embodiments, the lantibiotic is nisin, although the common structural features of lantibiotics dictate the effectiveness of the disclosed purification methods for other members of the lantibiotic genus. The method includes the step of forming an incubation mixture comprising the solution containing the lantibiotic and a proteolytic enzyme, and incubating the mixture under conditions optimized for selective proteolytic activity.
Abstract: Disclosed is a method for delivering an active protein or peptide to the colon. The steps of the method include providing a multiparticulate dosage core particle comprising 3 components, the total weight of the 3 components in dry form defining a batch size. The multiparticulate core particle is produced by the method comprising: a) providing an aqueous PEG solution, the dry weight of the PEG component representing from about 2.5% to about 15% of the batch size (weight/weight), the water component of the aqueous PEG solution representing approximately 30-60% of the batch size (weight/weight); b) providing a homogenous mixture of the active protein or peptide and microcrystalline cellulose, both in dry form, the active protein or peptide comprising from about 50% to about 95% of the batch size (weight/weight) and the microcrystalline cellulose comprising from about 2.
Abstract: Embodiments of the present invention relate to methods and articles of manufacture for the detection of Giardia cysts and Crytosporidium oocysts.
Abstract: Disclosed are methods and kits for the detection of Cryptosporidium oocysts and Giardia cysts. Such methods include the concentration of a water sample to form a retentate followed by resolution the retentate by density centrifugation. At least one layer is formed which retains the microbes to be detected. The presence of microbes within resolved layers is then detected.
Abstract: The present invention is directed to a process of isolating immunoglobulins from whey or whey concentrate and a concentrated immunoglobulin product which is highly purified. The process features the co-precipitation of lipids and non-immunoglobulin proteins simultaneously with a charged polymer and a fatty acid.